Option and Evaluation Partnership Terms & Agreements in Pharma, Biotech and Diagnostics: Global Market Report 2010-2017 - ResearchAndMarkets.com

DUBLIN--()--The "Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017" report has been added to ResearchAndMarkets.com's offering.

This report provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2010 to 2017.

Key Benefits

  • In-depth understanding of option and evaluation deal trends since 2010
  • Analysis of the structure of option and evaluation agreements with numerous real life case studies
  • Comprehensive access to over 1,000 actual option and evaluation deals entered into by the world's biopharma companies
  • Detailed access to actual option and evaluation contracts enter into by the leading fifty big pharma companies
  • Insight into the terms included in a option and evaluation agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

This report provides the reader with the following key benefits:

  • In-depth understanding of option and evaluation partnering deal trends since 2010
  • Insight into the terms included in an option and evaluation agreement, together with real world clause examples
  • Identify leading option and evaluation deals by value since 2010
  • Identify the most active option and evaluation dealmakers since 2010
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of option and evaluation deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 1,000 option and evaluation deals entered into by the world's biopharma companies, together with contract documents if available
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

Chapter 3 - Overview of option and evaluation deal structure

Chapter 4 - Leading option and evaluation deals

Chapter 5 - Top 50 most active option and evaluation dealmakers

Chapter 6 - Option and evaluation contracts directory

For more information about this report visit https://www.researchandmarkets.com/research/kj89gj/option_and?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics